Table 4.
Information about IF and cancer.
| Information | Method | Sample feature | Results | Discussion |
|---|---|---|---|---|
| Cooper [45] | Nonrandomized controlled experiments on animals |
n = 105 Male Fox Chase SCID mice injected in the flank with 1 × 105 LAPC-4 cells were randomized to seven groups |
IGF-1↓; survival percentage↑ (after 20 days) | Tumor growth was not significantly inhibited, but the survival rate was improved. |
| Stefanie [46] | Randomized controlled experiments in humans |
n = 131 HER2-negative II/III breast cancer patients |
Toxicity grade III/IV of the subjects (NA); DNA damage in T lymphocytes↓ | FMD has significant benefits in increasing the sensitivity of breast cancer cells to chemotherapy. |
| Cui [47] | Nonrandomized controlled experiments on animals | IF group (n = 8) AL group (n = 8) |
TFR, TV, damage to the liver caused by liver cancer↓ | IF can reduce tumorigenesis, inhibit tumorigenesis, reduce the degree of liver injury during tumorigenesis, and maintain normal lipid metabolism. |
Note: SCID: severe combined immunodeficiency; LAPC-4: Los Angeles prostate cancer-4; NA: not analyzed; TFR: tumor formation rate; TV: tumor volume; Glu: blood glucose.